Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2018 /
Practical approach to the management of the axilla after neoadjuvant chemotherapy

4th - 8th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.12.18
Views: 667

Dr Andrea Barrio - Memorial Sloan Kettering Cancer Centre, New York, USA

Dr Andrea Barrio speaks to ecancer at SABCS 2018 about the practical approach to the management of the axilla after neoadjuvant chemotherapy

She explains that the prospective trials that have demonstrated that the false negative rate of sentinel lymph node biopsy in clinically node positive patients after neoadjuvant chemotherapy exceeded the 10% considered to be clinically acceptable but that the number of sentinel nodes received can modify the false negative rate.

She explains that in a recently published meta analysis it was seen that the false negative rate was reduced to 4% when 3 or more sentinel nodes were removed.
 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation